moneyheap
TFX · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Teleflex Incorporated (TFX) stock moving?
Teleflex's Q3 2026 results beat expectations, with adjusted EPS of $2.63 against a $1.90 estimate and sales of $567.8M slightly above the $566.8M estimate. Reported revenue was flat year over year (+0.2%), and pro forma adjusted constant currency growth was 3.0%, within the maintained 3.5%-4.5% full-year range. Management said results included IEEPA tariff refunds, and GAAP EPS of $1.30 compares with a prior-year loss. Full-year adjusted EPS guidance was raised to $7.50-$7.75 from $6.90-$7.20, while full-year sales guidance was trimmed by about $4M to $2.256B-$2.276B. The company also reported about $350M of share repurchases since July 1 and said it is working to close the Acute Care and Interventional Urology divestiture by year-end, subject to regulatory approval. Analysts responded with higher targets: RBC raised to $175 (Outperform), while Wells Fargo (Equal-Weight) and Truist (Hold) both moved to $167. Price action confirms the positive reaction. The stock rose from $139.95 on Nov 3 to $149.87 on Nov 4, ahead of the Nov 5 release, then reached a 30-day high of $156.67 on Nov 5 on the window's heaviest volume (1.42M shares). It closed at $155.30 on Nov 10, about 11% above the Nov 3 close, while daily volume eased to 748K. The stock is near the top of its 30-day range (130.48-156.67), so the upside is largely reflected in the price. The main risks are the pending divestiture, the trimmed sales outlook, and a Hold-rated analyst view that sits below the current price.
News behind the analysis
- Teleflex Reports Third Quarter Financial Results and Full Year 2026 OutlookQ3 revenue from continuing operations was $567.8M, up 0.2% reported and 3.0% pro forma adjusted constant currency, with adjusted diluted EPS of $2.63 versus $1.89 a year earlier. The company raised its 2026 adjusted EPS guidance to $7.50-$7.75 and kept its 3.5%-4.5% pro forma constant currency revenue growth guidance.
- Teleflex Q3 Adj. EPS $2.63 Beats $1.90 Estimate, Sales $567.800M Beat $566.772M EstimateAdjusted EPS beat consensus by about 38%, and sales slightly beat the estimate. GAAP diluted EPS from continuing operations was $1.30, versus a loss of $(1.32) a year earlier.
- Teleflex Raises FY2026 Adj EPS Guidance from $6.90-$7.20 to $7.50-$7.75 vs $7.22 Est; Lowers FY2026 Sales Guidance from $2.260B-$2.280B to $2.256B-$2.276B vs $2.269B EstFull-year adjusted EPS guidance was raised by about $0.60 at the midpoint, above the $7.22 estimate. Full-year sales guidance was trimmed by $4M at both ends, to $2.256B-$2.276B.
- Teleflex Raises FY2026 GAAP EPS Guidance from $2.54-$2.84 to $2.84-$3.09 vs $4.13 EstGAAP EPS guidance was raised to $2.84-$3.09, though it remains below the $4.13 estimate. The company reported that Q3 results included IEEPA tariff refunds.
- RBC Raises Price Target on Teleflex to $175 From $155, Keeps Outperform RatingRBC Capital Markets raised its price target from $155 to $175 and kept its Outperform rating. The target is about 13% above the Nov 10 close of $155.30.
- Truist Securities Maintains Hold on Teleflex, Raises Price Target to $167Truist kept its Hold rating and raised its price target to $167. The target is about 8% above the Nov 10 close.
- Wells Fargo Maintains Equal-Weight on Teleflex, Raises Price Target to $167Wells Fargo kept an Equal-Weight rating and raised its price target to $167. The move is consistent with the broader post-earnings target increases.
- Teleflex Declares Quarterly Cash DividendThe Board declared a quarterly cash dividend of $0.34 per share of common stock.
About Teleflex Incorporated
Teleflex is a medical device maker based in Wayne, Pennsylvania, founded in 1943, that makes single-use products used in hospital procedures. In 2026 it sold its Acute Care, Interventional Urology (UroLift) and OEM businesses, leaving a smaller company focused mainly on vascular, interventional (including heart stents from its Biotronik vascular deal) and surgical products.
How it makes money
It sells disposable devices to hospitals and clinics around the world. These include vascular access catheters, interventional cardiology products such as stents and catheters, and surgical tools such as ligation clips and closure devices. After the divestitures, revenue from continuing operations runs at roughly $570 million a quarter (about $2.3 billion a year), with Vascular and Surgical as the main growth areas. Proceeds from the asset sales are going toward paying down debt and buying back shares.
What usually moves TFX
- Procedure volumes at hospitals
- Integration of the acquired vascular intervention business
- Use of divestiture proceeds for debt reduction and buybacks
- Tariffs and margin pressure
- New product approvals such as FDA designations